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Abstract
Background: Methuosis is a unique form of non-apoptotic cell death triggered by alterations in the trafficking of
clathrin-independent endosomes, ultimately leading to extreme vacuolization and rupture of the cell.
Results: Here we describe a novel chalcone-like molecule, 3-(2-methyl-1H- indol-3-yl)-1-(4-pyridinyl)-2-propen-1-
one (MIPP) that induces cell death with the hallmarks of methuosis. MIPP causes rapid accumulation of vacuoles
derived from macropinosomes, based on time-lapse microscopy and labeling with extracellular fluid phase tracers.
Vacuolization can be blocked by the cholesterol-interacting compound, filipin, consistent with the origin of the
vacuoles from non-clathrin endocytic compartments. Although the vacuoles rapidly acquire some characteristics of
late endosomes (Rab7, LAMP1), they remain distinct from lysosomal and autophagosomal compartments,
suggestive of a block at the late endosome/lysosome boundary. MIPP appears to target steps in the endosomal
trafficking pathway involving Rab5 and Rab7, as evidenced by changes in the activation states of these GTPases.
These effects are specific, as other GTPases (Rac1, Arf6) are unaffected by the compound. Cells treated with MIPP
lose viability within 2-3 days, but their nuclei show no evidence of apoptotic changes. Inhibition of caspase activity
does not protect the cells, consistent with a non-apoptotic death mechanism. U251 glioblastoma cells selected for
temozolomide resistance showed sensitivity to MIPP-induced methuosis that was comparable to the parental cell
line.
Conclusions: MIPP might serve as a prototype for new drugs that could be used to induce non-apoptotic death
in cancers that have become refractory to agents that work through DNA damage and apoptotic mechanisms.
Background
Cancer cells typically harbor mutations in tumor sup-
pressor genes that control programmed cell death, ren-
dering them relatively insensitive to apoptosis.
Moreover, many tumors that initially respond to treat-
ment with standard chemotherapeutic drugs eventually
develop multi-drug resistance due to increases in drug
efflux mechanisms or DNA repair capacity [1,2]. These
challenges have stimulated interest in identifying alter-
native cell death pathways that might be used to kill
tumor cells that have ceased to respond to drugs that
depend on induction of apoptotic mechanisms.
Several different forms of non-apoptotic cell death have
been described, based on specific morphological or
molecular criteria [3,4]. These include death associated
with accumulation of autophagosomes [5-7], as well as
several types of caspase-independent cell death that may
represent specialized forms of necrosis; e.g., oncosis
[8-10], necroptosis [11,12] and paraptosis [13,14]. More
than a decade ago Chi et al. [15] reported a unique type
of non-apoptotic cell death that can be induced in glio-
blastoma and gastric carcinoma cells by constitutive sti-
mulation of Ras signaling pathways. We have shown that
this form of cell death is distinct from other kinds of
non-apoptotic death noted above [16]. It involves stimu-
lation of macropinocytosis (cell drinking), combined with
defects in clathrin-independent endocytic vesicle traffick-
ing, ultimately resulting in accumulation of large vacuoles
that disrupt cellular membrane integrity. We have
termed this form of cell death ‘methuosis’, from the
Greek methuo, to drink to intoxication. Mechanistically,
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the effects of Ras overexpression are related to activation
of Rac1 and inactivation of Arf6, two GTPases implicated
in macropinocytosis and endosome recycling, respec-
tively [17].
Since our initial description of Ras-induced methuo-
sis, others have reported similar forms of cell death
associated with accumulation of macropinosome-
derived vacuoles in various contexts, including: treat-
ment of TrkA-positive medulloblastoma cells with
nerve growth factor [18], exposure of neurons to
methamphetamine [19], and treatment of prostate can-
cer cells with a nucleolin-binding oligonucleotide apta-
mer, AS1411 [20]. These studies lend credence to the
idea that methuosis may represent a non-apoptotic cell
death mechanism of some general importance. How-
ever, the potential for exploiting this non-conventional
cell death pathway to kill cancer cells that are refrac-
tory to apoptosis will depend on the identification of
molecules with drug-like properties that can induce
methuosis. Toward this end, we now describe a chal-
cone-related compound that can induce cell death with
the hallmarks of methuosis in both temozolomide-
resistant and non-resistant glioblastoma cells. This
compound may serve as a prototype for a new class of
therapeutic agents that could be used to treat tumors
that are resistant to conventional drugs.
Results
Small Molecules that Induce Cytoplasmic Vacuolization
We began our search for drug-like compounds that
might induce methuosis by surveying the literature for
reports of molecules that cause forms of cell vacuoliza-
tion resembling that induced by overexpression of acti-
vated H-Ras in glioma and other cancer cell lines
[15-17]. We noted a report from Kirchhausen and col-
leagues [21] in which they described a group of 16
vacuole-inducing compounds (vacuolins) identified in an
image-based phenotypic screen of the Chembridge
Diverset E library. Thirteen of the compounds had simi-
lar triazine-based core structures, and the most potent
of these was named vacuolin-1. The vacuoles induced
by vacuolin-1 were found to originate from inappropri-
ate homotypic fusion and swelling of endosomes and
lysosomes, but vacuolin-1 was reported not to interfere
with cell growth or viability [21]. In surveying the
remaining uncharacterized vacuole-inducing compounds
mentioned in this study, one unique molecule, 3-(5-
bromo-1H-indol-3-yl)-1-(4-pyridinyl)-2-propen-1-one
(Figure 1, compound I), captured our attention because
of its resemblance to chalcones, naturally occurring fla-
vonoid precursors with a 1,3-diphenyl- 2-propen-1-one
framework [22]. Synthetic derivatives built on the chal-
cone framework have recently been shown to exhibit
anti-cancer activity [22-24].
We found that compound I caused a striking accumu-
lation of numerous phase-lucent cytoplasmic vacuoles
within 4 h when applied to U251 glioblastoma cells
(Figure 1). When added at a concentration of 1 μM, the
morphological effects of compound I were transient,
with most of the vacuoles dissipating by 24 h (Figure 1).
However, at 10 μM, the morphological effects of com-
pound I persisted for 24 h and beyond. A search of the
broader 700,000 compound Chembridge collection
yielded several additional compounds with >75% similar-
ity to compound I. Of these, 3-(2-methyl-1H- indol-3-
yl)-1-(4-pyridinyl)- 2-propen-1-one (Figure 1, compound
II), behaved similarly to compound I when tested at 1
μM, but induced vacuoles that were larger and more
numerous than those induced by compound I when
tested at a concentration of 10 μM (Figure 1). Closely
related compounds with similar or identical indole ring
structures, but with variations in the second aryl ring
(compound III) or the enone linker (compound IV),
showed no vacuole-inducing activity (Figure 1). This
suggested that the effects of compounds I and II were
probably due to their interactions with specific intracel-
lular targets, rather than non-specific effects on cellular
membranes or intracellular pH. Compound III had no
vacuole-inducing activity despite the fact that it shared
the characteristics of a Michael acceptor with com-
pounds I and II. This makes it unlikely that the activities
of compounds I and II were due to general covalent
protein modification by Michael addition [25,26]. Based
on these initial observations, compound II was selected
for further study as a potential small molecule inducer
of methuosis. Hereafter it will be referred to by the
acronym MIPP: i.e., 3-(2-methyl-1H indol-3-yl)-1-(4-
pyridinyl)-2-propen-1-one.
The Origin of the Vacuoles Induced by MIPP is Consistent
with Methuosis
We first wished to determine if the vacuoles induced by
MIPP were derived from macropinosomes, since this is
a hallmark of methuosis. Macropinocytosis is a form of
clathrin-independent endocytosis wherein intracellular
vesicles are initially generated from projections of the
plasma membrane termed ruffles or lamellipodia, which
surround and trap extracellular fluid [27]. Time lapse
phase-contrast microscopy covering the period between
13-80 min after addition of MIPP revealed waves of
macropinocytotic vesicles entering the U251 cells from
regions of active membrane ruffling. The nascent vesi-
cles could be seen coalescing with each other to form
progressively larger vacuoles within the cytoplasm
(Figure 2A and Additional file 1, Movie 1). Time lapse
studies performed after the first 95 min revealed a
decline in the initial burst of macropinocytotic activity,
although the vesicles already formed within the cell
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continued to enlarge by undergoing occasional fusion
events (Additional file 2, Movie 2).
One of the features of methuosis, as previously
defined in glioblastoma cells expressing activated H-Ras,
is the incorporation of fluid-phase tracers like Lucifer
yellow (LY) into large vacuoles that eventually fill the
cytoplasm and disrupt the cells [16]. Therefore, to con-
firm that the MIPP-induced vacuoles observed by
phase-contrast microscopy were indeed derived from
macropinosomes, U251 cells were incubated with LY
during the first 4 h after addition of the compound. As
shown in Figure 2B, LY was incorporated into most of
the phase-lucent vacuoles.
Macropinocytosis, which is a clathrin-independent
form of endocytosis, depends on the integrity of choles-
terol-rich membrane microdomains [28]. There is evi-
dence that binding and sequestration of cholesterol by
treatment of cells with filipin selectively impairs cla-
thrin-independent endocytosis, while clathrin-dependent
receptor mediated endocytosis is unaffected [29]. There-
fore, to establish that the MIPP-induced vacuoles were
indeed derived from clathrin-independent compart-
ments, U251 cells were pre-incubated with or without
filipin for 30 min prior to adding MIPP. As shown in
Figure 2C, cells treated with MIPP in the absence of
filipin formed numerous vacuoles within the first 100
min after addition of the compound. In contrast, the
cells treated with filipin failed to show the typical mor-
phological response to MIPP. Thus, the majority of the
vacuoles induced by MIPP appear to originate from cla-
thrin-independent macropinosomes, consistent with the
mechanism of methuosis.
Relationship of MIPP-Induced Vacuoles to Other
Subcellular Compartments
In Ras-induced methuosis, the accumulated vacuoles
eventually acquire some characteristics of late endo-
somes, but remain separate from the endoplasmic reti-
culum and the lysosomal or autophagosomal
degradative compartments [16]. The vacuoles induced
by MIPP clearly fit this profile. Live cell imaging of the
phase-lucent vacuoles induced by MIPP showed no
overlap with compartments labeled with LysoTracker
Red, which identifies lysosomes based on their acidic
pH, or Magic Red (RR), a cell permeable substrate that
fluoresces when cleaved by the lysosomal protease,
cathepsin B (Figure 2B). Nor did the vacuoles incorpo-
rate ER-Tracker, a marker for the endoplasmic reticu-
lum (Figure 2B). Finally, the absence of labeling
with MitoTracker Red (Figure 2B) indicates that the
Figure 1 Compounds, I and II, induce extreme cytoplasmic vacuolization in U251 glioblastoma cells. Cells were seeded at 500,000 cells in
60 mm dishes. The day after plating, cells were treated with either 1 μM or 10 μM of the indicated compounds. Phase-contrast images were
taken 4 h and 24 h after addition of the drugs. The scale bar is 10 microns and applies to all of the panels. The appearance of the cells treated
with compounds III and IV was identical to control cultures treated with an equivalent volume of DMSO (not shown). Compound II was selected
for further study and was designated MIPP.
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phase-lucent vacuoles were not derived from swollen
mitochondria.
Although early endosomes are not sufficiently acidic
to label with LysoTracker (the lumen is maintained
around pH 6.2 [30]), maturation to late endosomes
depends on further acidification. Bafilomycin A1 (Baf-A)
is a specific inhibitor of the vacuolar-type H+-ATPase,
which plays critical role in the maintenance of endoso-
mal membrane potential and lumenal pH [31]. Previous
studies have shown that inhibition of H+-ATPase with
Baf-A impedes the formation of vesicular intermediates
between early and late endosomes [32]. Moreover, Baf-A
strongly inhibits homotypic endosome fusion in vitro
[33], blocks endosomal vacuolization induced by H.
Figure 2 Vacuoles induced by MIPP are derived from macropinosomes that undergo progressive fusion events and accumulate at a
pre-lysosomal stage. A) Time-lapse phase-contrast microscopy of U251 cells treated with MIPP. Images were captured at 30 sec intervals
during the period between 13-80 min after the addition of 10 μM MIPP, and the images were assembled into a movie, which is available as
Movie 1 (Additional file 1). The panels show sequential snapshots from the movie, with the elapsed time after addition of MIPP (min) indicated.
Newly formed macropinosomes can be seen fusing with each other to form larger vacuoles. The small two-headed arrows point to vesicles that
have fused in the subsequent frame. B) U251 cells were treated with 10 μM MIPP for 4 h, then incubated with the indicated fluorescent tracer or
organelle marker, as described in Materials and Methods. The same field of cells is depicted in the matching phase-contrast and fluorescent
images. In the top panel, the arrows indicate some of the specific vacuoles that have incorporated the Lucifer yellow. C) Cells were pretreated
for 30 min with 12 μg/ml filipin or an equivalent volume of vehicle (DMSO), then 10 μM MIPP was added to the cultures. Phase-contrast images
were acquired 100 min after the addition of the MIPP. D) Bafilomycin A1 (Baf-A) blocks the induction of vacuoles by MIPP. Cells were pretreated
for 1 h in the presence (+) or absence (-) of 100 nM Baf A prior to addition of MIPP (+MIPP) or DMSO (-MIPP). Phase-contrast images were taken
1 h after addition of MIPP. The scale bars in all of the images represent 10 microns.
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pylori [34], and disperses giant endosomes generated in
cells expressing constitutively active Rab 5 [35]. There-
fore, we asked whether or not the formation of vacuoles
in cells treated with MIPP requires the activity of the H
+-ATPase. As shown in Figure 2D, short-term (1 h)
incubation of U251 cells with Baf-A by itself had no
morphological effect on the cells, but the inhibitor com-
pletely abrogated the ability of the cells to generate
vacuoles when they were exposed to MIPP. The effect
of Baf-A appeared to be specifically related to disruption
of the endosomal membrane potential rather than gen-
eral alkalinization of the endosomal compartment, since
incubating cells with 1-5 mM ammonium chloride did
not replicate the effects of Baf-A (data not shown).
Finally, we examined the distribution of markers for
early and late endosomes and autophagosomes in cells
treated with MIPP. Confocal microscopy demonstrated
that by 24 h essentially all of the vacuoles contained late
endosomal markers, GFP-Rab7 and LAMP1, but showed
little or no overlap with early endosomes (EEA1), recy-
cling endosomes (Rab11), or autophagosomes (LC3II)
(Figure 3). Interestingly, the presence of the late endo-
some marker, Rab7, was detected in membranes of the
vacuoles as soon as 30 min after the addition of MIPP,
whereas the early endosome marker, Rab5, was generally
absent from the majority of the vacuoles (Additional file
3, Fig. S1). Taken together with the previous studies,
these observations support the idea that cellular vacuoli-
zation induced by MIPP involves fusion of nascent
macropinosomes to form large vacuoles that rapidly
mature to acquire some characteristics of late endo-
somes. However, these structures do not merge with
lysosomes or autophagosomes.
MIPP Affects the Activities of Endosomal Rab GTPases,
but not Rac1 or Arf6
To begin to explore the molecular mechanism(s)
through which MIPP causes endosomal vacuolization,
we considered possible parallels with the mechanism of
methuosis triggered by over-expression of activated H-
Ras. In the latter case, we found that development of
the vacuolar phenotype requires activation of the Rac1
GTPase, with a concomitant reduction in the activation
state of another GTPase, Arf6 [17]. However, when
fusion proteins that bind specifically to the activated
forms of Rac1 or Arf6 were used in pull-down assays to
measure the activation states of these GTPases, we
found that treatment of cells with MIPP had no signifi-
cant effects on the amounts of active Rac1 (Figure 4A)
or Arf6 (Figure 4B) at either 4 h or 24 h after addition
of the compound. Consistent with this observation, we
determined that when U251 cells were incubated with
MIPP in the presence of EHT 1864, a highly specific
Rac inhibitor [36], there was no detectable effect on
vacuole formation (Additional file 4, Fig. S2). These stu-
dies indicate that the mechanism of vacuolization
induced by MIPP is different from that induced by Ras,
in that it does not depend on activation of the Rac1 sig-
naling pathway.
In light of the striking effects of MIPP on the clathrin-
independent endosomal compartment, we next focused
on the Rab5 and Rab7 GTPases, which are known to
function in early and late endosomal trafficking steps,
respectively [37]. The active GTP-bound forms of these
proteins were measured in pull-down assays using GST-
fusion constructs containing the Rab binding domains of
rabaptin-5, for Rab5 [38], or RILP, for Rab7 [39]. As
shown in Figure 4C, MIPP caused a significant decline in
the amount of active Rab5 at both 4 h and 24 h after
treatment. In contrast, MIPP had the opposite effect on
Rab7, with the amount of active Rab7 more than dou-
bling by 24 h (Figure 4D). The change in active Rab7 at
24 h was moderated somewhat (but still significant)
when the results were normalized to the total Rab7 pool.
This is due to the fact that the total amount of Rab7 in
the MIPP treated cells increased substantially by 24 h. It
is important to note that the changes in the Rab activity
were observed only in cells treated with the vacuole-
inducing compound, MIPP. For example, in cells treated
with the related but inactive compound III (see Figure 1),
there was no change in the activation state of Rab7 (Fig-
ure 4E). In summary, these results suggest that the
vacuolization of macropinosome-derived endocytic com-
partments in MIPP-treated cells is associated with oppo-
site changes in the pools of active Rab5 and Rab7.
To determine if the initial MIPP-induced decrease in
active Rab5 is the primary defect responsible for the
chain of events that leads to methuosis, we over-
expressed constitutively active GFP-Rab5(Q79L) in cells
treated with MIPP to see if it might compensate for the
loss of endogenous Rab5-GTP. The results indicate that
Rab5(Q79L) was unable to prevent MIPP-induced
vacuolization or restore cell viability (Additional file 5,
Fig. S3). A caveat is that Rab5(Q79L) itself has a ten-
dency to promote the formation of giant endosomes by
triggering homotypic fusion of early endosomes, as
noted in previous reports [35,40]. However, these struc-
tures never become as large or as numerous as the
vacuoles induced by MIPP. In any case, the results show
that simply augmenting the intracellular pool of active
Rab5 is not sufficient to block the effects of MIPP. Simi-
larly, overexpression of dominant-negative GFP-Rab7
(N125I) to counteract the increase in endogenous Rab7-
GTP also failed to prevent methuosis induced by MIPP
(Additional file 5, Fig. S3). This supports the idea that
the accumulation of active Rab7 is a consequence rather
than a direct cause of the endosomal trafficking defects
triggered by MIPP.
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Figure 3 Vacuoles induced by MIPP acquire characteristics of late endosomes, but remain distinct from autophagosomes. U251 cells
expressing GFP-Rab7 were treated with 10 μM MIPP and then processed for immunofluorescence microscopy. Confocal imaging was used to
localize endogenous LAMP1, EEA1, LC3II and Rab11 (red) relative to the GFP-Rab7 (green). The scale bars are 10 microns.
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MIPP Induces Non-Apoptotic Cell Death with the
Characteristics of Methuosis
We next conducted a series of studies to determine how
closely the sequelae of MIPP treatment match the cell
death phenotype associated with methuosis. As reported
previously [16], the initial accumulation of vacuoles in
glioblastoma cells undergoing Ras-induced methuosis is
followed by a decline in cellular ATP levels, cell round-
ing, and detachment of cells from the substratum. Cell
death ensues as the vacuoles expand to fill most of the
cytoplasmic space and cell membrane integrity is dis-
rupted. Characteristically, these alterations are not
accompanied by morphological changes typical of apop-
tosis, such as nuclear chromatin condensation, nuclear
fragmentation or cell shrinkage. Although caspase acti-
vation can be detected by examining PARP cleavage,
cell death by methuosis cannot be prevented by treat-
ment with caspase inhibitors. The studies described in
Figures 5 and 6 indicate that the form of cell death
induced by MIPP in U251 glioblastoma cells shares all
of these characteristics.
As shown in Figure 5A, both of the vacuole-inducing
compounds, MIPP and compound I, caused a marked
decrease in cell growth and relative cell viability, mea-
sured by MTT assay, during the first two days of treat-
ment. In contrast, the structurally related compounds III
and IV that did not cause cellular vacuolization (Figure
1) had little effect on cell growth/viability during the
same period (Figure 5A). By the second day after addi-
tion of MIPP, the cells exhibited a significant decrease
in the level of ATP and a decline in mitochondrial
membrane potential (Figure 6A &6B), indicative of
metabolic compromise.
However, there was no general increase in reactive
oxygen species in the MIPP-treated cells (Figure 6C).
On the contrary, the level of ROS in the MIPP-treated
cells was significantly lower than in the controls.
We noted that the number of rounded and detached
cells increased dramatically in the MIPP-treated cultures
between days 2 and 3 (Figure 5B). Cells that had been
treated with 10 μM MIPP for 2 days were essentially
non-viable when evaluated in colony-forming assays
(Figure 5C). Further evaluation of the MIPP-treated
cells by electron microscopy revealed that both the
attached and detached cells contained numerous large,
mostly empty, vacuoles bounded by a single membrane
(Figure 5D). These structures were indistinguishable
morphologically from the vacuoles induced by activated
Ras in previous studies [16]. In the detached cells, the
vacuoles had typically expanded to the point where they
displaced much of the cytoplasmic volume and, in many
cases, the plasma membrane was disrupted (Figure 5D,
arrows). Of particular note, even in highly vacuolated
cells that appeared on the verge of lysis, the nuclear
Figure 4 MIPP affects the activation states of Rab5 and Rab7,
but not Rac1 or Arf6. In separate experiments U251 cells were
treated with 10 μM MIPP for the indicated periods of time and then
harvested for pull down assays to measure the relative amounts of
active Rac1 (A), Arf6 (B), Rab5 (C) or Rab7 (D), as described in
Materials and Methods. In each case the values for active GTPase
(left graph) or active/total GTPase (right graph) were expressed as
the percent of the corresponding values for parallel control cultures
that received an equivalent volume of vehicle (DMSO), indicated by
the dashed line in each graph. As an additional control, the studies
of Rab7 were conducted with cells treated with the inactive
compound III instead of MIPP (E). Results are the means (± SD)
compiled from three separate experiments. Values marked with an
asterisk were significant at p ≤ 0.05 compared with the controls.
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Figure 5 MIPP-induced vacuolation leads to non-apoptotic cell death in glioblastoma cells. A) MTT assay of U251 cells treated over time
with the indicated compounds (refer to Fig. 1 for structures) at a concentration of 10 μM. Each point represents the mean (± SD) of results from
quadruplicate wells. The decreases in viability of the cells treated with MIPP (▲) or compound I (●) were significant at p < 0.001 on days 2 and 3.
B) Phase-contrast images of U251 cells treated for 2 or 3 days with 10 μM MIPP. The arrows point to vacuolated cells that have rounded and
detached from the surface of the dish. The scale bar is 10 microns. C) U251 cells were treated with 10 μM MIPP or an equivalent volume of
DMSO (control) for 2 days and colony forming assays were performed as described in Materials and Methods. The results shown are the mean
(± SD) of triplicate dishes, with representative dishes shown at the right. The decrease in the number of colonies for the MIPP-treated cells (*)
was significant at p < 0.001. D) U251 cells were examined by electron microscopy after two days of treatment with 10 μM MIPP. The left panel
(att) is a representative image of an attached cell and the right panel (det) is representative of a cell that had detached from the dish. The
arrows point to regions of plasma membrane discontinuity indicative of cell rupture. Nuclei (N) do not show changes in chromatin distribution
typical of apoptosis. The scale bars are 10 microns. E) U251 cells treated with 10 μM MIPP for 2 days are negative for TUNEL staining. F)
Inhibition of caspase activity does not prevent MIPP-induced cell death. U251 cells were seeded at 350,000 cells per 60 mm dish. The next day
cells were treated with 10 μM MIPP or an equivalent volume of DMSO, in the presence or absence of 50 μM z-VAD-fmk. After two days the
attached and detached cells were pooled and harvested for immunoblot analysis of PARP. MTT assays were performed on cells treated in the
same manner, except that they were seeded in a 96-well plate. Values are means (± SD) of quadruplicate samples.
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chromatin remained diffuse and the nuclear membrane
appeared intact (Figure 5D). Consistent with this obser-
vation, staining the MIPP-treated cells by TUNEL did
not reveal evidence of nucleosomal DNA fragmentation
(Figure 5E). These observations were suggestive of a
non-apoptotic death mechanism. To confirm this, we
asked whether the broad spectrum caspase inhibitor,
zVAD-fmk, could prevent cell death in U251 glioblas-
toma cells treated with MIPP (Figure 5F). Similar to our
previous observations with Ras-induced methuosis, the
dying cells treated with MIPP showed some evidence of
caspase activation (i.e., cleavage of full-length PARP to
an 82 kDa fragment). However, caspase activation was
not necessary for cell death. That is, even though
zVAD-fmk was able to block PARP cleavage by caspase,
it did not prevent the loss of viability in the MIPP-trea-
ted cells (Figure 5F). When combined with the lack of a
morphological signature for apoptosis, these findings
support our hypothesis that MIPP-induced cell death is
independent of caspase activation and is due mainly to
metabolic crisis and physical disruption of the highly
vacuolated cells.
Since brief treatment with 100 nM Baf-A was able to
impede the initial formation of vacuoles in cells treated
with MIPP (Figure 2D), we considered the possibility
that continued incubation of U251 cells in medium with
Baf-A might counteract the cytotoxic effects of MIPP.
However, these studies were hindered by the confound-
ing effects of Baf-A itself on endosomal trafficking,
which can result in vacuolization of late endosomes [41]
and inhibition of cell growth and viability [42]. We
found that prolonged incubation of U251 cells with 50
nM Baf-A alone caused accumulation of vacuoles by 24
h and eventually led to cell death (Additional file 6, Fig.
S4).
MIPP Produces Similar Effects in a Broad Spectrum of
Cancer Cells, Including Drug-Resistant Glioblastoma
To assess the possibility that the observed response to
MIPP might be a unique feature of the U251 glioblas-
toma cell line, we examined the effects of the compound
in several other cell lines. These included an additional
glioma cell line (LN229), osteosarcoma cells (U2OS),
and breast (MCF7), colon (SW480) and pancreatic
(PANC-1) carcinoma cells. Similar to the results with
U251 cells, 10 μM MIPP induced dramatic cytoplasmic
vacuolization in all of the cell lines (Additional file 7,
Fig. S5). Although there were some differences in sensi-
tivity, relative cell viability determined by MTT assays
was generally reduced by 50-90% in all of the cancer
cell lines treated with MIPP. Colony forming assays con-
firmed that exposure to MIPP for 2 days significantly
reduced long-term cell survival in all cases (Additional
file 7, Fig. S5). In the same study we also examined the
Figure 6 Deficiency of mitochondrial energy metabolism
accompanies cell death in cells treated with MIPP. For all graphs
the solid bars are values for cells treated with 10 μM MIPP and the
open bars are controls treated with an equivalent volume of DMSO.
A) ATP levels were measured as described in the Methods. The
decrease in ATP in MIPP-treated cells on day-2 (*) was significant at
p < 0.02 compared to the cells treated with DMSO. B) Mitochondrial
membrane potential was evaluated using the JC-1 assay. The
significant decline (p < 0.0001) in the ratio of fluorescence emission
at 600 nm vs. 535 nm on day-2 signifies a disruption of
mitochondrial membrane potential. C) There is no increase in
intracellular ROS associated with MIPP-induced cell death, based on
measuring the fluorescence of the ROS indicator, H2DCFDA. The
decline in ROS in the MIPP-treated cells on day-2 was significant at
p < 0.005.
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effects of MIPP on normal human skin fibroblasts and
an established mammary epithelial cell line (MCF-10A).
Although these cell lines also underwent extensive cyto-
plasmic vacuolization, the reductions in cell viability
(30% for MCF-10A and 40% for fibroblasts) were more
moderate than what we observed for the cancer cell
lines.
Our initial interest in MIPP and related compounds
was based on the premise that because they induce cell
death by a non-apoptotic mechanism, involving pertur-
bations of vesicular trafficking rather than DNA replica-
tion/repair, they might be useful against cancers that
have acquired resistance to drugs that work by dama-
ging DNA. To test this hypothesis, we derived temozo-
lomide-resistant clones from the U251 glioblastoma cell
line. The survival study depicted in Figure 7A shows an
example of one such clone (U251-TR), which was highly
resistant to TMZ in comparison to the parental U251
cell line. When U251-TR cells were treated with 10 μM
MIPP, they underwent extensive vacuolization identical
to that observed in the parental U251 cells (Figure 7B).
MTT dose-response curves indicated that both the par-
ental U251 and U251-TR cells were sensitive to MIPP
over a 2-day period (Figure 7C), although the relative
IC50 value for the resistant cells (6.0 μM) was slightly
higher than for the parental cells (3.5 μM). As in the
case of the parental U251 cells (Figure 5C), treatment of
the U251-TR cells resulted in a significant decline in
survival, assessed by colony forming assays (Figure 7D).
Similar results were obtained with additional TMZ-resis-
tant clones (not shown).
Discussion
Glioblastomas are highly aggressive brain tumors that
almost always recur after surgery. Treating these tumors
is extremely challenging because the residual cells are
highly invasive [43] and they typically harbor genetic
mutations that decrease their sensitivity to apoptosis
[44,45]. The mainstays for adjuvant therapy of glioblas-
toma are radiation and TMZ [46]. TMZ has been
reported to cause senescence and apoptosis in glioblas-
toma [47], but sensitivity to TMZ-induced apoptosis is
blunted in cells with tumor suppressor mutations (e.g.,
p53) [48]. There is some evidence that TMZ may be
able to overcome the intrinsic resistance of glioblastoma
to apoptosis by inducing autophagic cell death [49,50].
Nevertheless, glioblastomas ultimately develop resistance
to TMZ through a combination of factors, including
alterations in DNA repair capacity [51,52]. The discov-
ery of novel cell death mechanisms that do not depend
on DNA damage could present new opportunities to
treat these devastating tumors. Along sthese lines,
Lefranc et al. [53] have reported that targeting the a1
subunit of the Na+/K+-ATPase, which is highly
Figure 7 MIPP has similar effects on cell morphology and
viability in temozolomide-resistant (U251-TR) and parental
(U251) glioblastoma cells. A) Cells were treated with the indicated
concentrations of TMZ for 48 h. Colonies were counted as
described in Materials and Methods and the results were expressed
as the percentage of the mean value for parallel control plates for
the same cell lines without drug. Each point is the mean from three
plates (± SD). B) Phase-contrast images were obtained after
treatment of cells for 48 h with 10 μM MIPP or an equivalent
volume of DMSO (control). C) MTT assays were performed after
treatment for 48 h with the indicated concentrations of MIPP or an
equivalent volume of DMSO. The quadruplicate MTT values for the
MIPP-treated wells were expressed as percent of the mean for the
parallel DMSO-treated wells. Relative IC50 values were calculated
from nonlinear regression analysis of sigmoidal dose response
curves plotted with GraphPad Prizm 4.0 (La Jolla, CA). D) U251-TR
cells were treated with 10 μM MIPP or an equivalent volume of
DMSO (control) for 2 days and colony forming assays were
performed. The results shown are the mean (± SD) of triplicate
dishes, with representative dishes shown at the right. The decrease
in the number of colonies for the MIPP-treated cells (*) was
significant at p < 0.001.
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expressed in glioblastoma, can induce cytotoxic pro-
autophagic effects in a pre-clinical model of glioblas-
toma. However, it is not yet known whether this
approach can work against TMZ-resistant glioblastoma
cells.
We recently described a unique form of cell death that
is distinct from autophagy and other non-apoptotic
forms of death. This form of death, termed methuosis,
can be triggered by ectopic expression of constitutively
activated Ras in glioblastoma and other cancer cell lines
[16,17]. In this study we have identified a small mole-
cule termed MIPP, which is capable of inducing the
hallmark cytopathological features of methuosis by
directly interfering with vesicular trafficking in the endo-
cytic pathway. Shortly after being exposed to MIPP,
glioblastoma cells exhibit a massive influx of macropino-
cytotic vesicles. In our time-lapse studies, the latter can
be seen undergoing fusion events to form larger
vacuoles that rapidly acquire late endosomal characteris-
tics (Rab7, LAMP1). However, the vacuoles do not
appear to merge with lysosomal compartments. Ulti-
mately, displacement of much of the cytoplasmic space
by the accumulated vacuoles is accompanied by a
decline in metabolic activity and rupture of the cell.
Consistent with a non-apoptotic mechanism, these
changes cannot be prevented by caspase inhibitors, and
nuclear chromatin condensation and TUNEL staining
typical of apoptosis are not observed.
A key finding is that glioblastoma cells selected for
resistance to TMZ are susceptible to MIPP-induced
methuosis. We have recently obtained similar results
comparing doxorubicin-resistant versus non-resistant
MCF-7 breast cancer cells treated with a structural ana-
log of MIPP (to be described in a separate report). This
raises the intriguing possibility that MIPP may serve as
a prototype for development of drugs that could be used
to trigger death by methuosis in drug-resistant cancers.
Although compounds related to MIPP could have
potential as novel therapeutic agents, MIPP itself may
not be an ideal choice for in vivo testing at the present
time. One of the problems we have noted is the limited
solubility of the compound in aqueous solutions. We
are currently attempting to address this issue by synthe-
sizing a directed library of related compounds to better
understand the structure-activity relationships and to
identify more potent derivatives with more versatile
solubility properties. In this regard, the initial compari-
sons of MIPP with the inactive compounds included in
this report, as well as with other unpublished analogs,
provide some helpful insights. For example, activity
seems to require the presence of both an electron-rich
heteroaryl system (the indole ring) and an electron defi-
cient heteroaryl system (the pyridine ring). Modifica-
tions to either ring structure can abolish activity, even if
the chalcone-like 2-propen-1-one bridge is retained.
This level of structural specificity argues against the idea
that MIPP might serve as a broad-spectrum Michael
inhibitor, and indicates that the effects of MIPP on
endocytic vesicular trafficking and cell viability are most
likely related to interactions with specific intracellular
protein targets.
Clues concerning the steps involved in MIPP-induced
methuosis come from a consideration of the pathways
for macropinocytosis in mammalian cells. Macropino-
somes are normally internalized through an actin-
dependent process that requires sequential recruitment
of phosphatidylinositol 4,5-bisphosphate and phosphati-
dylinositol 3,4,5-trisphosphate [54,55]. Once interna-
lized, macropinosomes rapidly acquire Rab5, EEA1 and
sorting nexins, which promote fusion with early endo-
somes [56,57]. The latter retain the capacity to recycle
to the cell surface [55], but after several additional min-
utes they lose Rab5 and acquire Rab7 and LAMP1, tak-
ing on the characteristics of late endosomes [57,58].
Ultimately, the fluid-filled vesicles dissipate as they
merge with lysosomes [58]. Our finding that MIPP initi-
ally causes a significant decrease in the activity of Rab5,
followed by an increase in the activity of Rab7 suggests
a working model depicted in Figure 8. We hypothesize
that MIPP targets one or more proteins in endosomal
complexes required for fusion of nascent macropino-
somes with early endosomes, directly or indirectly
affecting the guanine nucleotide cycle of Rab5. This pre-
vents the vesicles formed during the initial burst of
macropinocytotic activity from entering the early and
recycling endosomal compartments. This is consistent
with the general absence of Rab5, EEA1 and Rab11
from the vacuoles.
The vesicles that bypass the normal endosomal traf-
ficking pathway immediately recruit Rab7 and begin to
undergo abnormal homotypic fusions to form progres-
sively larger LAMP1-positive structures (Figure 8). Pre-
cedent for such an endosomal ‘bypass’ mechanism has
recently been described for a macropinocytosis-like
pathway used by BTV-1 virus to infect BHK cells. In
this system, clathrin-independent vesicles carrying the
virus rapidly merge with LAMP1-positive late endo-
somes without passing through early or recycling endo-
some compartments [59]. It remains unclear why the
Rab7-positive vacuoles are able to fuse with each other
but cannot merge with lysosomes or autophagosomes.
One possibility is that in bypassing the normal endoso-
mal trafficking route the vacuoles fail to acquire key
proteins needed for heterotypic tethering and fusion
with lysosomes (e.g., HOPS, trans-SNARE) [60,61]. This
model could also explain the eventual increase in the
amount of Rab7-GTP, as GAP-mediated GTP-hydrolysis
that normally accompanies endosome-lysosome fusion
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would fail to occur. An important goal for the future
will be the precise identification of the molecular targets
of MIPP. Given the efficacy of MIPP against TMZ-resis-
tant cells, possible candidates might be found among
the list of genes recently shown to be induced in TMZ-
resistant glioblastoma cells [62]. However, because of
the complexity of the trafficking pathways underlying
the methuosis phenotype, we believe that unbiased
approaches to drug target discovery will stand the best
chance of defining the relevant targets of the compound.
Based on our examination of several cancer cell lines,
it seems clear that the ability of MIPP to induce
methuosis extends beyond glioblastoma. While broad-
spectrum activity against a variety of cancers ultimately
may prove to be a positive attribute, the observation
that MIPP can also trigger vacuolization and a modest
reduction of cell proliferation/viability in normal prolif-
erating cells, raises a note of caution. Eventual testing of
MIPP-related compounds in vivo may need to incorpo-
rate approaches for selective delivery of such com-
pounds to tumors. In this regard, recent advances in
tumor targeted drug delivery strategies [63-65] should
provide a number of options. Given the potential value
of a therapeutic agent that can induce non-apoptotic
death in drug-resistant cancer cells, we believe that
further development of MIPP-related compounds, iden-
tification of their specific molecular targets, and investi-
gation of their therapeutic properties are worthwhile
goals.
Methods
Test Compounds and Reagents
Compounds I, II (MIPP), and IV were purchased from
Chembridge Corporation (San Diego, CA). Compound
III was purchased from TimTec, LLC (Newark, DE).
Each of these compounds was stored at-20°C as a 5 mg/
ml stock solution in DMSO, and then diluted to the
indicated final concentration in cell culture medium.
Filipin, bafilomycin A1 and temozolomide (TMZ) were
obtained from Sigma-Aldrich (St. Louis, MO). Filipin
was stored at -20°C as a 50 mg/ml stock in DMSO and
bafilomycin A1 was stored at -20°C as a 10 μM stock in
DMSO. EHT 1864 was generously provided by Exonhit
Therapeutics, Paris, France. z-VAD-fmk was purchased
from Bachem (Torrance, CA).
Cell Culture
U251 human glioblastoma cells were purchased from
the DCT Tumor Repository (National Cancer Institute,
Frederick, MD). All other cell lines were obtained from
Figure 8 A working model for MIPP-induced methuosis suggested by the present studies: The earliest visible effect of the compound
involves stimulation of macropinosome influx. Interaction of MIPP with unidentified components of the nascent macropinosomes results in a
decline in active Rab5 and deficient delivery of macropinosomes to the early endosome sorting compartment. This precludes recycling or
maturation to normal multivesicular and late endosomes. The abnormal macropinosomes undergo homotypic fusion and rapidly acquire some
characteristics of late endosomes (e.g., LAMP1 and Rab7). However, they apparently lack key molecular components required for fusion with
lysosomes. Consequently, they accumulate as vacuoles and eventually fill the cell, impairing metabolic function (decrease in ATP and
mitochondrial membrane potential) and disrupting membrane integrity.
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the American Type Culture Collection (Rockville, MD).
Cell lines were passaged for fewer than six months prior
to use. Normal human skin fibroblasts were derived
from a skin biopsy as described previously [66]. Unless
stated otherwise, cell lines were maintained in Dulbec-
co’s modified Eagle medium (DMEM) with 10% (v/v)
fetal bovine serum (FBS) (JR Scientific, Woodland, CA)
at 37°C with 5% CO2/95% air. MCF-10A cells were
maintained in DMEM + Ham’s F12 (1:1) containing
5.0% horse serum, 20 ng/ml EGF, 0.5 μg/ml hydrocorti-
sone, 100 ng/ml cholera toxin, and 10 μg/ml insulin, as
described [67]. Colonies of TMZ-resistant U251 cells
were selected by maintaining the parental U251 cells in
medium containing 100 μM TMZ for 24 days, with
replenishment of the medium and drug every three
days. Colonies were then picked and plated into a 12-
well dish and exposed to escalating concentrations of
TMZ. The clone used in the present study (U251-TR) is
maintained routinely in medium with 300 μM TMZ.
Phase-contrast images of live cells were obtained using
an Olympus IX70 inverted microscope equipped with a
digital camera and SPOT imaging software (Diagnostic
Instruments, Inc., Sterling Heights, MI).
Live Cell Imaging with Fluorescent Tracers
Lucifer yellow (LY) was purchased from Invitrogen/
Molecular Probes (Carlsbad, CA). Labeling of endocytic
compartments with this fluid-phase tracer was per-
formed as previously described [16]. Labeling of intra-
cellular acidic compartments with LysoTracker Red
DND-99 (Invitrogen) and staining for cathepsin B activ-
ity with Magic Red RR (ImmunoChemistry Technolo-
gies, Bloomington, MN) were performed as described
previously [16]. ER-Tracker Blue-White DPX (Invitro-
gen) was used to label the endoplasmic reticulum fol-
lowing the directions supplied by the manufacturer.
Cells were incubated with 200 nM MitoTracker Red
CMXRos (Invitrogen) in Hank’s balanced salt solution
for 20 min to label the mitochondria. Phase-contrast
and fluorescent images of the living cells were acquired
on an Olympus IX70 inverted microscope equipped
with a digital camera and SPOT imaging software or on
a Nikon Eclipse TE2000U fluorescence microscope with
a digital camera and NIS-Elements AR software (Nikon
Instruments, Inc., Melville, NY).
Time-Lapse Microscopy
200,000 U251 cells were plated in a 35 mm glass-bot-
tom microwell culture dish (MatTek, Ashland, MA).
The day after plating, the cells were treated with 10 μM
MIPP in phenol red-free DMEM supplemented with
10% FBS. The dish was immediately placed in a humidi-
fied Live Cell chamber (Pathology Devices, Westminster,
MD) equilibrated with 5% CO2 at 37°C. The chamber
was placed on the stage of an Olympus IX80 inverted
microscope, equipped with a digital camera and Slide-
book software (Intelligent Imaging Innovations, Inc.,
Denver, CO). The software was set to automatically
acquire phase-contrast images every 30 sec for the indi-
cated period of time.
Treatment of Cells with Filipin, Bafilomycin A1 or EHT
1864
To inhibit clathrin-independent endocytosis, U251 cells
were washed twice with serum-free DMEM, then pre-
treated for 30 min with DMEM + 0.5% BSA in the pre-
sence or absence of 12 μg/ml filipin [29]. Following the
pretreatment, MIPP was added to the dishes at a final
concentration of 10 μM and phase-contrast images were
acquired 100 min later.
To inhibit the vacuolar-type H+ ATPase, U251 cells
were pretreated for 1 h with 50 or 100 nM bafilomycin
A1 (Baf-A) or an equivalent volume of DMSO, as indi-
cated in the figure legends. At the end of the hour, 10
μM MIPP, or an equivalent volume of DMSO, was
added without a medium change.
Phase-contrast images of the cells were acquired 1 h
after the addition of MIPP. To determine the effect of
MIPP and Baf-A on cell growth, 35 mm dishes were
seeded with 100,000 cells one day prior to exposure to
the drugs. At the indicated times after treatment, tripli-
cate dishes of cells were harvested by trypsinization and
counted with a Coulter Z1 particle counter (Beckman
Coulter, Brea, CA).
To determine if inhibition of the Rac1 GTPase would
block the accumulation of vacuoles, U251 cells were
treated for 24 h with 10 μM MIPP in the presence or
absence of 25 μM EHT 1864 (Rac inhibitor). The per-
centage of vacuolated cells in the population was deter-
mined by scoring at least 100 cells in multiple phase-
contrast photomicrographs for each condition. Cells
containing three or more phase-lucent vacuoles with
diameters ≥ 0.5 μm or >10 smaller vacuoles (0.1-0.5
μm) were scored as positive. For comparison, the effect
of EHT 1864 on Ras-induced vacuolization was also
determined. U251 cells were nucleofected with pCMV5-
Myc-H-Ras(G12V), as described previously [68], then
immediately plated into medium with or without 25 μM
EHT 1864. After 24 h, phase-contrast images were
taken and the number of vacuolated cells was scored as
described above.
Pull-Down Assays to Measure the Activation States of
GTPases
Assays for activated Rac1 and Arf6 were performed as
described previously [17] using EZ-Detect Rac1 or Arf6
activation kits (Thermo Scientific Pierce, Rockford, IL).
These assays employ either a GST-fusion protein
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containing the p21-binding domain of p21-activated
protein kinase 1 (PAK1) to selectively bind active Rac1
in whole cell lysates, or GST-GGA3 (Golgi-associated
gamma adaptin ear-containing Arf binding protein 3) to
pull down active Arf6. The active Rac1 or Arf6 collected
on the glutathione beads were subjected to western blot
analysis and the chemiluminescence signals were quanti-
fied using Alpha Innotech FluorChem HD2 imaging sys-
tem. The values for active protein in each sample were
normalized to a-tubulin. Results were expressed as
either the total active Rac1 or Arf6, or the ratio of the
active GTPase to the total Rac1 or Arf6 measured in ali-
quots of the cell lysate.
Prokaryotic expression vectors encoding GST-RILP or
GST-Rabaptin-5 (C-terminus) were kindly provided by
Cecilia Bucci (University of Salento, Italy) and José A.
Esteban (Universidad Autónoma de Madrid, Spain),
respectively. GST-fusion proteins were produced in E.
coli BL21 (DE3) pLysS (Promega, Madison, WI, USA)
and the fusion proteins were bound to glutathione-
sepharose 4B beads (GE Healthcare Biosciences, Pitts-
burgh, PA, USA). Pull-down assays for active Rab5
using the GST-Rabaptin-5 beads were performed essen-
tially as described by Brown et al. [38]. Assays for active
Rab7 were performed as described by Romero Rosales et
al. [69]. For each determination cell lysates were pre-
pared from ten pooled 10 cm cultures. Monoclonal anti-
bodies against Rab5 or Rab7 (Cell Signaling
Technologies, Danvers, MA) were used to probe western
blots of the proteins collected on the beads. Results
were quantified and normalized essentially as described
above for Rac1 and Arf6.
Effects of Dominant-Negative or Constitutively Active Rab
Constructs on Methuosis
pEGFP-C1 was purchased from Clontech (Mountain
View, CA), pEGFP-Rab5(Q79L) was provided by
Guangpu Li, University of Oklahoma College of Medi-
cine, and pEGFP-Rab7(N125I) was provided by Cecilia
Bucci, University of Salento. U251 cells were nucleo-
fected with pEGFP-C1, pEGFP-Rab5(Q79L) or pEGFP-
Rab7(N125I) as previously described [68]. The cells
were plated either in 35 mm dishes for live cell imaging
or 96-well plates for MTT assay. The day after nucleo-
fection, the cells were treated with 10 μM MIPP or an
equivalent volume of DMSO and cells were monitored
by MTT assays or phase contrast and fluorescence
microscopy.
Confocal Fluorescence Microscopy
U251 cells were nucleofected with pEGFP-Rab7 or
pEGFP-Rab5, then plated onto coverslips in 60 mm
dishes. The day after nucleofection, the cells were trea-
ted with 10 μM MIPP. For colocalization experiments,
cells that had been treated with MIPP for 24 h were
prepared for immunofluorescence microscopy as
described previously [70]. Antibodies to detect endogen-
ous LAMP1 (Developmental Studies Hybridoma Bank,
University of Iowa, Iowa City, IA), EEA1 (Abcam, Cam-
bridge, MA), LC-3 (Abgent, Inc., San Diego, CA), and
Rab11 (Invitrogen) were obtained from the indicated
sources. In a previous study we found that the LC3 anti-
body predominantly recognizes the autophagosomal
form of LC3, LC3II [16]. All primary antibodies were
detected by incubation with goat anti-mouse IgG conju-
gated to Alexa Fluor 568 (Invitrogen). Cells were exam-
ined by confocal microscopy using a Leica TCS SP5
system with 488- and 561-nm laser excitation. Images
were acquired with the LASAF software on the system.
Electron Microscopy
U251 cells were exposed to 10 μM MIPP for 48 h, then
prepared for electron microscopy as described pre-
viously [70]. The cells were examined under a Philips
CM 10 transmission electron microscope.
Western Blot Analysis
The antibody for PARP was purchased from BD Bios-
ciences (San Jose, CA). Methods for protein determina-
tion, SDS-PAGE and western blot analysis have been
described previously [71].
Cell Viability
Cell viability was measured using a 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)-based
assay. A 5 mg/ml MTT (Amresco, Solon, OH) stock
solution was prepared in phenol-red free RPMI 1640
(Mediatech, Inc, Herndon, VA). Cells were seeded in
96-well plates, with four replicate wells for each culture
condition. On the day of the assay, 10 μl of the MTT
solution was added directly to 100 μl in each well and
the cells were incubated for 3-4 h at 37°C, with 5% CO2.
At the end of the incubation, 100 μl of MTT solvent
(0.1N HCl in isopropanol, containing 0.1% NP-40) was
added to each well. The plates were incubated for an
additional 5 min at 37°C, 5% CO2, then quantified for
absorbance at 570 nm on a SpectraMax Plus 384 plate
reader (Molecular Devices, Sunnyvale, CA).
For colony-forming assays, cells were plated in 100
mm dishes at 2,500 (U251 and U251-TR) or 1,500 (all
other cell lines) cells per dish. Beginning on the day
after plating, the cells were exposed to 10 μM MIPP for
2 days, with the medium and drug replenished after 1
day. The cells were fed fresh medium without drug
every 2 to 3 d for a period of 10-21 days. To visualize
the colonies, the dishes were washed with PBS, fixed for
10 min with ice-cold 100% methanol, and stained with
1% crystal violet (Acros Organics, Fisher Scientific,
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Pittsburgh, PA) in 35% methanol. After 2-3 washes with
water, colonies containing at least 50 cells were counted
using a dissecting microscope or a Protocol 2 colony
counter (Synbiosis, Frederick MD).
Nuclear DNA fragmentation resulting from apoptotic
cell death was assayed using the DeadEnd Fluorometric
TUNEL System from Promega according to the manu-
facturer’s protocol, including the use of DNAse I treat-
ment as a positive control. U251 cells were seeded at
500,000 cells in 60 mm dishes containing a coverslip.
Treatment with 10 μM MIPP or an equal volume of
DMSO began one day after plating, with medium and
drug being replenished each day until the TUNEL assay
was performed.
To compare the levels of ATP in MIPP-treated glio-
blastoma cells versus controls treated with an equivalent
volume of DMSO, the cells were harvested by trypsini-
zation and assayed using the CellTiter Glo kit from Pro-
mega (Madison, WI) according to the manufacturer’s
instructions. The effect of MIPP treatment on the elec-
trochemical gradient across the mitochondrial mem-
brane was determined using the JC-1 Mitochondrial
Membrane Potential Detection Kit from Biotium (Hay-
ward, CA), following the manufacturer’s recommended
protocol. Reactive oxygen species (ROS) were measured
using the 5-(and -6)-carboxy-2’,7’-dichlorodihydrofluor-
escein diacetate (H2DCFDA) reagent from Invitrogen.
U251 cells were seeded in phenol red-free DMEM +
10% FBS at 5,000 cells per well in black 96-well plates
the day before treatment. Quadruplicate wells were trea-
ted with 10 μM MIPP, or an equal volume of DMSO.
At the indicated times, the medium was removed and
the cells were loaded with 100 μM H2DCFDA in HBSS
for 30 min, 37°C, 5% CO2. After removing the loading
buffer, the cells were washed twice with HBSS, then
incubated for additional 30 minutes in HBSS prior to
quantification of the fluorescence.
Statistical Significance
Statistical significance of differences in colony formation
or other parameters (e.g., GTPase activation) involving
comparisons between control and MIPP-treated cells
were evaluated by Student’s two tailed t-test.
Additional material
Additional file 1: Movie 1. Quick Time movie showing the evolution of
vacuoles derived from macropinosomes in U251 cells treated with 10 μM
MIPP. Time-lapse phase-contrast images were captured at 30 sec intervals
and assembled into a movie that covers the period between 13-80 min
after the addition of the compound. Macropinosomes can be seen
forming from regions of active membrane ruffling, and then fusing with
each other to form larger vacuoles. The larger vacuoles migrate toward
the perinuclear region, where they accumulate.
Additional file 2: Movie 2. Quick Time movie showing U251 cells
during the period following the initial burst of macropinocytotic activity,
between 95-160 min after addition of 10 μM MIPP. Time-lapse phase-
contrast images were captured at 30 sec intervals. Very few new
macropinosomes form during this period. Fusions of existing vacuoles
continues to occur but at a much slower rate than during the first 90
min after addition of MIPP.
Additional file 3: Figure S1. U251 cells were transfected with
expression vectors encoding GFP-Rab5 or GFP-Rab7. After 24 h, MIPP was
added at a concentration of 10 μM and cells were examined by confocal
fluorescence microscopy at the indicated intervals. The results show that
even at the earliest time points most of the vacuoles are decorated with
Rab7. In contrast, Rab5 is mostly localized in smaller punctate structures.
The scale bars are 10 microns.
Additional file 4: Figure S2. The Rac inhibitor, EHT 1864, does not block
the induction of vacuoles by MIPP. U251 cells were incubated with MIPP
for 24 h in the presence or absence of 25 μM EHT 1864 (panel A). In a
separate experiment, U251 cells were incubated with or without EHT
1864 following nucleofection with a vector encoding a constitutively
active H-Ras(G12V) (panel B). Phase-contrast images were taken 24 h after
addition of the Rac inhibitor. The scale bars are 10 microns. C) The
percentage of vacuolated cells for each condition was determined as
described in Materials and Methods.
Additional file 5: Figure S3. Expression of constitutively active Rab5 or
dominant-negative Rab7 does not protect U251 cells from MIPP-induced
methuosis. A) Cells were nucleofected with vectors encoding GFP or
constitutively active GFP-Rab5(Q79L), as indicated above each panel. One
day after nucleofection (time-0) parallel cultures were treated with 10 μM
MIPP (○) or an equivalent volume of DMSO (●) and viable cells were
measured by MTT assay. Cells in parallel dishes were subjected to
fluorescence and phase contrast microcopy to evaluate the extent to
which the nucleofected cells (green) were vacuolated. B) The identical
experiment was conducted with cells expressing GFP or the dominant-
negative GFP-Rab7(N125I).
Additional file 6: Figure S4. Long-term treatment of U251 cells with
Bafilomycin A1 (Baf-A) induces vacuolization and is cytotoxic. Therefore,
Baf-A cannot protect cells from MIPP-induced methuosis. U251 cells were
treated for 2 days with the indicated compounds. A) Cells were
examined by phase contrast microscopy to assess vacuolization. B) Cell
growth was assessed by counting attached cells in 3 parallel cultures
(mean ± SD) at each time point. The symbols are: DMSO control (■), 10
μM MIPP alone (▲), 50 nM Baf-A alone (○), or a combination of 10 μM
MIPP plus 50 nM Baf-A (●).
Additional file 7: Figure S5. MIPP induces vacuoles and inhibits growth
and viability in multiple human cell lines. Cell lines examined were:
LN229, glioblastoma; SW480, colon adenocarcinoma; PANC-1, pancreatic
carcinoma; U20S, osteosarcoma; MCF-7, mammary adenocarcinoma;
MCF-10A, mammary epithelial cells; primary human skin fibroblasts. A)
Phase-contrast images of cells were acquired after two days of treatment
with 10 μM MIPP. The scale bars are 10 microns. B) MTT assays were
performed on cells treated for the indicated number of days with 10 μM
MIPP or an equivalent volume of DMSO. The MTT values for the MIPP-
treated wells were expressed as percent of the mean for the parallel
DMSO-treated wells. Error bars indicate the SD. C) Colony-forming assays
for the transformed cell lines were preformed as described in Materials
and Methods. Values are the mean (± SD) from triplicate cultures. All of
the decreases in colony formation (*) were significant at p < 0.001.
Abbreviations
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dimethyl sulfoxide; FBS: fetal bovine serum; GAP: GTPase activating protein;
GFP: green fluorescent protein; GST: glutathione S-transferase; HBSS: Hank’s
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